Nutrients, Vol. 18, Pages 1751: Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
Nutrients doi: 10.3390/nu18111751
Authors:
Zambrano-Villacres
Campuzano-Donoso
Reytor-González
Rossetti
Cobellis
Cobellis
Pilone
Simancas-Racines
Schiavo
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependentinsulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed obesitytreatment, producing substantial weight loss during active therapy. However, realworldeffectiveness may be limited by gastrointestinal adverse events, reduced dietaryintake, fat-free mass loss as part of total weight reduction, and weight regain after discontinuation.Methods: This narrative review synthesizes current pharmacological, nutritional,gastrointestinal, body-composition, and implementation evidence to propose anevidence-informed nutrition-first framework for patients receiving incretin-based therapyfor obesity. Results: We translate pharmacologic mechanisms into practical dietary strategies,including protein prioritization, structured meal patterns, hydration and fiber management,symptom-targeted interventions, resistance-training support, and maintenanceplanning. Because direct trials of structured nutrition interventions in GLP-1RA- or dualincretin-treated populations remain limited, several recommendations are extrapolatedfrom the broader obesity, caloric restriction, body-composition, gastrointestinal, and expert-consensus literature. Conclusions: Integrating structured nutrition care into pharmacotherapypathways may help address meal-related symptom burden, support proteinand fluid adequacy, identify patients at higher nutritional or body-composition risk, andprepare patients for long-term weight-management behaviors. Embedding practical nutritionmanagement within multidisciplinary obesity care may help translate pharmacologicefficacy into durable, patient-centered outcomes.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependentinsulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed obesitytreatment, producing substantial weight loss during active therapy. However, realworldeffectiveness may be limited by gastrointestinal adverse events, reduced dietaryintake, fat-free mass loss as part of total weight reduction, and weight regain after discontinuation.Methods: This narrative review synthesizes current pharmacological, nutritional,gastrointestinal, body-composition, and implementation evidence to propose anevidence-informed nutrition-first framework for patients receiving incretin-based therapyfor obesity. Results: We translate pharmacologic mechanisms into practical dietary strategies,including protein prioritization, structured meal patterns, hydration and fiber management,symptom-targeted interventions, resistance-training support, and maintenanceplanning. Because direct trials of structured nutrition interventions in GLP-1RA- or dualincretin-treated populations remain limited, several recommendations are extrapolatedfrom the broader obesity, caloric restriction, body-composition, gastrointestinal, and expert-consensus literature. Conclusions: Integrating structured nutrition care into pharmacotherapypathways may help address meal-related symptom burden, support proteinand fluid adequacy, identify patients at higher nutritional or body-composition risk, andprepare patients for long-term weight-management behaviors. Embedding practical nutritionmanagement within multidisciplinary obesity care may help translate pharmacologicefficacy into durable, patient-centered outcomes. Read More